Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library
Pharmaceutics, Free Full-Text
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Frontiers Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments, Journal of Translational Medicine
Extracellular matrix and its therapeutic potential for cancer treatment
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. - Abstract - Europe PMC
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Cancers, Free Full-Text
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
de
por adulto (o preço varia de acordo com o tamanho do grupo)
